Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | RAC1 | P63000 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432310 | 0.93 | ITGB1 (0.62) | ITGB1ITGA4EPHB3CSNK2A1RAC1 | |
| SCHEMBL2432030 | 0.88 | ITGB1 (0.55) | ITGB1ITGA4CCR3ACKR3 | |
| SCHEMBL2432033 | 0.88 | ITGB1 (0.55) | ITGB1ITGA4CCR3ACKR3 | |
| SCHEMBL2432107 | 0.87 | ITGB1 (0.45) | ITGB1ITGA4KDM4EKCNH2 | |
| SCHEMBL2432104 | 0.87 | ITGB1 (0.45) | ITGB1ITGA4KDM4EKCNH2 | |
| SCHEMBL2433076 | 0.85 | ITGA4 (0.42) | ITGB1ITGA4 | |
| SCHEMBL2433079 | 0.85 | ITGA4 (0.42) | ITGB1ITGA4 | |
| SCHEMBL2435807 | 0.84 | ITGB1 (0.60) | ITGB1ITGA4ACKR3 | |
| SCHEMBL2435804 | 0.84 | ITGB1 (0.60) | ITGB1ITGA4ACKR3 | |
| SCHEMBL2435437 | 0.82 | ITGB1 (0.63) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885KDM4E 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.